Biotech: Page 20
-
Permission granted by Relay Therapeutics
Relay breast cancer drug shows potential in early trial
Results from a small study suggest Relay's drug could avoid some of the toxicity associated with existing PI3Ka inhibitors like Novartis' Piqray.
By Ned Pagliarulo • Sept. 9, 2024 -
shutterstock.com/Juan Gaertner
Early study data puts Terns among obesity drug contenders
A once-daily pill the biotech is developing helped some people with obesity lose more than 5% of their weight in a month, spurring a stock bump and plans to bring the drug into further testing.
By Jonathan Gardner • Sept. 9, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Permission granted by Candid Therapeutics
Immune resetCandid, with $370M, sets out to prove bispecifics’ worth in autoimmune disease
The startup believes T cell engagers, rather than cell therapies, will prove the “right horse to bet on” in the race to develop new inflammatory disease treatments, its CEO said.
By Ben Fidler • Sept. 9, 2024 -
Stock.adobe.com
Sponsored by Quest DiagnosticsAccelerating Alzheimer’s therapy innovation: A new horizon in blood-based biomarkers
The escalating global challenge of Alzheimer's Disease (AD) demands new approaches to detection, diagnosis and treatment.
By Dr. Michael K. Racke, Medical Director, Neurology, Quest Diagnostics • Sept. 9, 2024 -
Daniel Tadevosyan via Getty Images
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise
OrsoBio is advancing several weight loss medicines. Elsewhere, Boehringer Ingelheim pushed forward with a geographic atrophy drug and Vaxcyte raised $1.3 billion.
By BioPharma Dive staff • Sept. 6, 2024 -
skynesher via Getty Images
Lykos CEO to depart after FDA rejection, layoffs
The departure of Amy Emerson as CEO comes three weeks after the MDMA developer revealed plans to cut 75% of its staff.
By Ned Pagliarulo • Sept. 5, 2024 -
Sundry Photography via Getty Images
BioMarin, having retrenched, outlines plans for growth
The biotech is putting Voxzogo, its drug for skeletal disorders, at the center of plans to grow revenue the rest of this decade and beyond.
By Delilah Alvarado • Sept. 4, 2024 -
Daniel Tadevosyan via Getty Images
High-dose Spinraza meets study goal; Top Dyne executives exit
A new dose regimen of Biogen's spinal muscular atrophy drug appeared promising, while Denali Therapeutics and Regenxbio charted plans for drug approval applications.
By BioPharma Dive staff • Sept. 4, 2024 -
Meletios Verras via Getty Images
ArsenalBio raises $325M in one of the year’s largest biotech funding rounds
The financing comes amid a slowdown in venture investment for gene and cell therapy startups, and will support multiple solid tumor programs.
By Gwendolyn Wu • Sept. 4, 2024 -
Daniel Tadevosyan via Getty Images
Novo builds heart failure case for semaglutide; Ventyx CFO departs
A new analysis showed semaglutide reduced the risk of worsening heart failure. Elsewhere, the FDA OK’d a vaccine for mpox and a biotech planned layoffs.
By BioPharma Dive staff • Aug. 30, 2024 -
Courtesy of BioMarin Pharmaceutical
BioMarin to lay off over 200 employees
The company has reshuffled its executive team, cut back spending and trimmed its drug pipeline this year, changes aimed at refocusing its resources.
By Delilah Alvarado • Aug. 29, 2024 -
Dr_Microbe via Getty Images
Cell and gene therapy investment, once booming, is now in a slump
Far fewer venture funding rounds were closed by cell and gene therapy developers over the first six months of 2024 than in prior years. Experts say there are several factors.
By Gwendolyn Wu • Aug. 29, 2024 -
Sean Gallup via Getty Images
Bayer partners with RNA drugmaker to develop new cancer therapies
Under a collaboration with NextRNA Therapeutics, Bayer will access the biotech’s platform to target long, non-coding RNA interactions with small molecule drugs.
By Delilah Alvarado • Aug. 28, 2024 -
Daniel Tadevosyan via Getty Images
RA Capital-backed startup raises $100M; UCB sells China business
New biotech Navigator is working on drugs for immune diseases. Meanwhile, UCB sold its neurology and allergy business in China, and J&J's Peter Fasolo will retire this year.
By BioPharma Dive staff • Aug. 27, 2024 -
Andrii Yalanskyi via Getty Images
Tome Biosciences to lay off over 100 employees
The buzzy startup, which had raised over $200 million in venture funding, is letting go of much of its workforce, according to a state regulatory notice.
By Delilah Alvarado • Aug. 26, 2024 -
Permission granted by Versant Ventures
Q&A // Emerging biotechVersant’s Jerel Davis on build-to-buy deals and pharma investment
Build-to-buy arrangements can give pharmaceutical companies an option to acquire a startup’s assets later, as with Novartis’ deal with the Versant-backed Borealis Biosciences.
By Gwendolyn Wu • Aug. 26, 2024 -
torwai via Getty Images
Sponsored by AltasciencesHow biotech companies and CROs can better align to accelerate development for the most promising discoveries
CROs are vital in supporting biotech with R&D. How can that relationship go from transactional to partnership?
Aug. 26, 2024 -
Permission granted by Menarini Silicon Biosystems
Sponsored by Menarini Silicon BiosystemsA truly comprehensive liquid biopsy approach: DLL3 and the rise of customized CTC and cfDNA/cfRNA analysis with CellSearch® and MenariniSearch
Imagine the power of combining CTCs, cell-free DNA and cell-free RNA.
Aug. 26, 2024 -
Michael M. Santiago via Getty Images
Two antibody startups file for IPOs amid summer slump
Armed with clinical-stage data, Zenas BioPharma and Bicara Therapeutics both fit the profile of biotechs that have successfully pulled off IPOs this year.
By Gwendolyn Wu • Aug. 23, 2024 -
Daniel Tadevosyan via Getty Images
FDA to convene immunotherapy panel; Tome scales back operations
Agency advisers will discuss whether use of Keytruda and Opdivo should be limited in gastric cancer. Elsewhere, a buzzy genetic drug startup is exploring “strategic options.”
By BioPharma Dive staff • Aug. 23, 2024 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
Updated COVID shots from Pfizer, Moderna cleared by FDA
Approval of the reformulated mRNA vaccines, which are designed to target the KP.2 virus strain, comes just ahead of the fall and winter seasons.
By Ned Pagliarulo • Aug. 22, 2024 -
Courtesy of Novartis
Versant reimagines its Chinook success with newest startup launch
Borealis Biosciences launches with money from Novartis, which last year bought the biotech’s predecessor for drugs that treat a rare kidney disorder.
By Gwendolyn Wu • Aug. 22, 2024 -
VisualCommunications via Getty Images
BridgeBio sends rare disease drugs to new company
Backed by $300 million from investors that include Viking Global Investors and Sequoia Capital, GondolaBio will inherit several BridgeBio drug programs.
By Ned Pagliarulo • Aug. 21, 2024 -
Courtesy of BioMarin Pharmaceutical
BioMarin taps Amgen, Roche vets in executive reshuffle
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
By Jacob Bell • Aug. 21, 2024 -
Daniel Tadevosyan via Getty Images
Avidity, Kymera raise fresh funds; Walgreens partners with BARDA
Avidity raised $345 million to advance development of RNA medicines designed to combine the advantages of oligonucleotides and antibodies.
By BioPharma Dive staff • Aug. 20, 2024
Previous
